Mainly patients with heart failure have a higher risk to develop CV death, actually much more than those type 2 diabetic patients who suffered a stroke or have peripheral artery disease or a myocardial infarction. The ones who have type 2 diabetes and heart failure have the highest risk of dying in follow-up. 
– Dr. Pieter Martens
SGLT2 inhibition: A consolidated view by an Endocrinologist and Cardiologist
During this e-learning, the link between type 2 diabetes and heart failure will be discussed followed by a deep-dive into the innovative class of SGLT2 inhibitors that is already widely used to treat type 2 diabetes patients. Curiosity around this class has grown since the read out of several cardiovascular and cardiorenal outcome trials showing the beneficial effects of the SGLT2 inhibitors on heart and kidneys. As we may expect this class to be used even more broadly by different specialists for many more patients in the future, we took the opportunity to let a Belgian cardiologist, specialist in heart failure and a Belgian professor in diabetology and endocrinology share their view on the use of the class in type 2 diabetic patients with or without heart failure by both focusing on their area of expertise.
- Dr. Pieter Martens
- Prof. Dr. Michel P. Hermans